Read by QxMD icon Read

Annals of Nuclear Medicine

Ahmet Murat Aydin, Bahadir Haberal, Meylis Artykov, Cenk Yucel Bilen, Sertac Yazici
OBJECTIVE: To demonstrate the effect of clinicopathological factors on 68 Ga-PSMA-11 PET/CT positivity at the time of biochemical recurrence (BCR) of localized prostate cancer (PCa) following definitive therapy. METHODS: We retrospectively reviewed our institutional database for PCa patients who had BCR and subsequently underwent 68 Ga-PSMA-11 PET/CT between April 2014 and February 2018. A total of 51 patients who were metastasis-free before PSMA imaging and previously treated with definitive therapy (radical prostatectomy or external beam radiotherapy) for localized disease (pT1c-T3b pN0-1 cM0) were included...
February 18, 2019: Annals of Nuclear Medicine
A E T Brito, F A Mourato, R P M de Oliveira, A L G Leal, P J A Filho, J L L de Filho
BACKGROUND: 68 Ga-PSMA-PET has an increasing importance in the evaluation of prostate cancer patients due to its high sensitivity and specificity in identifying neoplastic lesions in the clinical setting of elevated prostate-specific antigen (PSA). The objective of this study was to calculate the whole-body tumor burden using volumetric quantification of lesions detected in 68 Ga-PSMA-PET of prostate cancer patients with biochemical recurrence and correlate these findings with clinical and image parameters...
February 11, 2019: Annals of Nuclear Medicine
Miho Aoki, Akira Odani, Kazuma Ogawa
PURPOSE: Although it has been traditionally surmised that phosphatidylserine (PS) externalization is a hallmark of apoptosis, most other non-apoptotic modes of cell death, such as necrosis, are also associated with PS externalization. Bis(zinc-dipicolylamine) (ZnDPA) complexes have been reported to exhibit affinity for PS. The present study aimed to develop novel radiolabeled ZnDPA derivatives for cell death imaging in tumor after treatment with anticancer drugs. METHODS: [125 I]IB-EG2 -ZnDPA and [99m Tc]Tc-MAG3-EG2 -ZnDPA were designed and prepared...
February 6, 2019: Annals of Nuclear Medicine
Hideo Yamamoto, Shota Takemoto, Akira Maebatake, Shuhei Karube, Yuki Yamashiro, Atsushi Nakanishi, Koji Murakami
OBJECTIVE: Whole-body dynamic imaging using positron emission tomography (PET) facilitates the quantification of tracer kinetics. It is potentially valuable for the differential diagnosis of tumors and for the evaluation of therapeutic efficacy. In whole-body dynamic PET with continuous bed motion (CBM) (WBDCBM-PET), the pass number and bed velocity are key considerations. In the present study, we aimed to investigate the effect of a combination of pass number and bed velocity on the quantitative accuracy and quality of WBDCBM-PET images...
February 1, 2019: Annals of Nuclear Medicine
Yoichi Shimizu, Arata Motomura, Hideo Takakura, Nagara Tamaki, Yuji Kuge, Mikako Ogawa
OBJECTIVE: Macrophages play an essential role in immune response, and are closely related to the progression of diseases such as cancer and atherosclerosis. Macrophages polarize to M1 or M2 type, which is related to the environmental hypoxic state. Previously, we found that 18 F-FMISO uptake varied according to expression levels of biomolecules such as glutathione S-transferase P1 (GST-P1), which catalyzes the conjugation of glutathione to 18 F-FMISO metabolites, and multidrug resistance-associated protein 1 (MRP1), which exports glutathione-18 F-FMISO metabolite conjugates out of cells...
January 29, 2019: Annals of Nuclear Medicine
Chio Okuyama, Shigenori Matsushima, Motoki Nishimura, Kei Yamada
OBJECTIVE: Increased 18 F-fluorodeoxyglucose (FDG) uptake in the tonsils after the completion of chemotherapy in patients with lymphoma may be misdiagnosed as tumor recurrence. This study aimed to investigate the changes in physiological FDG uptake in the tonsils during and after chemotherapy in pediatric patients with lymphoma. METHODS: A total of 47 FDG-PET/CT scans acquired from 13 pediatric patients with lymphoma (before chemotherapy [preC] = 9; during chemotherapy [durC] = 12; within 1 month after the end of chemotherapy [endC] = 11; and after achieving complete response [postC] = 15) were retrospectively included in this study...
January 28, 2019: Annals of Nuclear Medicine
Matti J Kortelainen, Tuomas M Koivumäki, Marko J Vauhkonen, Mikko A Hakulinen
OBJECTIVE: Correction for respiratory motion in myocardial perfusion imaging requires sorting of emission data into respiratory windows where the intra-window motion is assumed to be negligible. However, it is unclear how much intra-window motion is acceptable. The aim of this study was to determine an optimal value of intra-window residual motion. METHODS: A custom-designed cardiac phantom was created and imaged with a standard dual-detector SPECT/CT system using Tc-99m as the radionuclide...
January 24, 2019: Annals of Nuclear Medicine
(no author information available yet)
No abstract text is available yet for this article.
January 23, 2019: Annals of Nuclear Medicine
Alireza Sadremomtaz, Mahboubeh Masoumi
OBJECTIVE: Bone-seeking radiopharmaceuticals have the main role in the treatment of painful bone metastases. The aim of this study was to dosimetrically compare radiopharmaceuticals in use for bone pain palliation therapy and bone scan. METHODS: The MCNPX code was used to simulate the radiation transport in a vertebral phantom. Absorbed fractions were calculated for monoenergetic electrons, photons and alpha particles. S values were obtained for radionuclides 32 P, 33 P, 89 Sr, 90 Y, 99m Tc, 117m Sn, 153 Sm, 166 Ho, 169 Er, 177 Lu, 186 Re, 188 Re, 223 Ra, 224 Ra and their progenies for target regions including the active marrow and the bone endosteum...
January 18, 2019: Annals of Nuclear Medicine
Christopher Silman, Shunro Matsumoto, Asami Ono, Maki Kiyonaga, Kenichiro Otsuka
OBJECTIVE: This study aimed to determine the level of 18 F fluorodeoxyglucose (18 F-FDG) activity in the normal adult appendix using positron emission tomography/computed tomography (PET/CT). MATERIALS AND METHODS: We performed a retrospective review of PET/CT images using 18 F-FDG in 563 consecutive asymptomatic adult patients without appendiceal pathology. We excluded 257 patients for an undetected or obscured appendix and three patients for appendicitis found on CT imaging...
January 16, 2019: Annals of Nuclear Medicine
Francesco Cicone, Luciano Carideo, Claudia Scaringi, Antonietta Arcella, Felice Giangaspero, Francesco Scopinaro, Giuseppe Minniti
OBJECTIVE: The role of amino acid positron emission tomography (PET) in glioma grading and outcome prognostication has not yet been well established. This is particularly true in the context of the new WHO 2016 classification, which introduced a definition of glioma subtypes primarily based on molecular fingerprints. The aim of the present study was to correlate 3,4‑dihydroxy‑6‑[18 F]‑fluoro-L‑phenylalanine (F-DOPA) uptake parameters with IDH mutation, 1p/19q status, and survival outcomes in patients with glioma...
January 3, 2019: Annals of Nuclear Medicine
Dominic T Mathis, Lukas Büel, Helmut Rasch, Felix Amsler, Michael T Hirschmann, Rolf W Hügli
OBJECTIVE: To evaluate the differences of bone tracer uptake (BTU) in symptomatic and asymptomatic contralateral knees in patients after reconstruction of the anterior cruciate ligament (ACL-R) and to identify typical BTU patterns and threshold values to differentiate pathological from physiological BTU. METHODS: 53 patients after unilateral ACL-R were retrospectively included in the study. The population was subdivided into a group of symptomatic operated knees and a group of contralateral asymptomatic non-operated knees...
January 3, 2019: Annals of Nuclear Medicine
Atsushi Ishizaki, Kenji Mishiro, Kazuhiro Shiba, Hirofumi Hanaoka, Seigo Kinuya, Akira Odani, Kazuma Ogawa
OBJECTIVE: Somatostatin receptors are highly expressed in neuroendocrine tumors, and many radiolabeled somatostatin analogs for diagnosis and treatment have been developed. To simultaneously detect not only primary cancer but also bone metastases, this study aimed to develop a positron emission tomography probe using generator-produced nuclide Gallium-68 (T1/2 = 68 min), in which a carrier for primary cancer, a carrier for bone metastases lesions, and a stable gallium complex are introduced into the one molecule...
January 3, 2019: Annals of Nuclear Medicine
Kenji Ishibashi, Masashi Kameyama, Kenji Ishii
No abstract text is available yet for this article.
January 2, 2019: Annals of Nuclear Medicine
Motoi Roppongi, Mitsuru Izumisawa, Kazunori Terasaki, Yasushi Muraki, Masanori Shozushima
OBJECTIVE: Among different PET tracers, 18 F-fludeoxyglucose (FDG) and 11 C-choline are known to have a high tumor uptake correlated with a high mitotic index of tumor cells. Thus, the uptake of 18 F-FDG and 11 C-choline may be dependent on the cell cycle. In the present study, we examined the uptake of 18 F-FDG and 11 C-choline in cancer cell lines by cell cycle synchronization to clarify the biological properties of cancer cells with respect to each tracer. METHODS: HeLa S3 Cells were synchronized by the double thymidine (TdR) block methods...
December 26, 2018: Annals of Nuclear Medicine
Silvia Taralli, Margherita Lorusso, Valentina Scolozzi, Valeria Masiello, Fabio Marazzi, Maria Lucia Calcagni
OBJECTIVE: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor recently approved for treatment in advanced or metastatic breast cancer (BC) patients. The use of 18 F-FDG PET/CT for chemo/endocrine therapy response assessment in BC patients is well reported in the literature, but no studies have evaluated its role for assessing Palbociclib efficacy in clinical practice. Our study aimed to evaluate the potential role of 18 F-FDG PET/CT in this setting. METHODS: In 12 metastatic BC patients (mean age = 62 ± 10 years) treated with Palbociclib plus endocrine therapy and who underwent a baseline and post-therapy 18 F-FDG PET/CT, we retrospectively compared the Metabolic Response Evaluation (MRE, based on PET/CT) to the Standard Response Evaluation (SRE, based on clinico-laboratory and morphological data); we also assessed the influence of additional PET/CT information on the patients' management...
December 19, 2018: Annals of Nuclear Medicine
Kamilla Bredlund Caspersen, Nikoletta Giannoutsou, Oke Gerke, Abass Alavi, Poul Flemming Høilund-Carlsen, Søren Hess
PURPOSE: Suspected serious disease (SSD) is a disease designation often given to patients with one or more non-specific symptoms of severe disease that could be due to cancer; the optimal diagnostic strategy is largely left to the clinician's discretion. Being a sensitive non-invasive whole-body imaging modality 18 F-FDG-PET/CT may have a potential role in this cancer-prevalent group of patients to confirm or refute suspected malignancy. We aimed to investigate the diagnostic value of 18 F-FDG-PET/CT in SSD using long-term follow-up as reference...
December 19, 2018: Annals of Nuclear Medicine
Linjue Shangguan, Shengwei Fang, Peipei Zhang, Suyang Han, Xiaodong Shen, Yawen Geng, Dingcun Luo, Chunlei Zhao
OBJECTIVE: To investigate the impact factors of the outcome of the first 131 I treatment in patients with papillary thyroid carcinoma (PTC) after total thyroidectomy. METHODS: Three hundred and fifty-three patients [256 females, 97 males, average age (43.58 ± 12.33 years)] with PTC after total thyroidectomy who underwent 131 I treatment from July 2014 to August 2017 were retrospectively analyzed. Curative efficacy of 131 I treatment was assessed 6 months afterward...
December 4, 2018: Annals of Nuclear Medicine
Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura, Sachiko Yanagida, Seigo Kinuya
Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastasis. Ra-223 improved overall survival in the international Phase III ALSYMPCA (ALpharadin in SYMPtomatic Prostate Cancer) study. Ra-223 was also demonstrated to be efficacious and safe in Japanese patients in Phase I and Phase II clinical trials. Ra-223 was approved in Japan for the treatment of patients with CRPC with bone metastasis in 2016...
November 27, 2018: Annals of Nuclear Medicine
Takahiro Fujiwara, Kuniyuki Hidaka, Keiichi Sugibayashi, Makoto Matsumoto, Tetsuo Kida, Katsuya Shiina
PURPOSE: In 2013, the Japanese Society of Nuclear Medicine (JSNM) announced consensus guidelines for pediatric nuclear medicine. These JSNM guidelines proposed use of lower administered doses compared with traditionally determined doses, which were estimated from age, weight or body surface area (BSA) based on the administered dose for adults in Japan. When the JSNM guidelines are used, the relationship between this recommended administered dose and image quality remains unclear. In this study, we clarified the relationship between administered dose and image quality for pediatric 99m Tc-DMSA renal scan retrospectively, and verified the diagnosable image quality with the recommended administered dose of the JSNM guidelines...
November 27, 2018: Annals of Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"